IL17A and neoplasm: In summary, the composition of the tumor microenvironment, the presence of immunosuppressive cytokines (IL-17 and IL-4), and Tregs should be evaluated before γδ T cell immunotherapy to minimize the risk of treatment failure in the clinical setting.